{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:35:46Z","timestamp":1793205346616,"version":"4.5.0"},"reference-count":91,"publisher":"The Korean Society of Nephrology","issue":"6","license":[{"start":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T00:00:00Z","timestamp":1658188800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Croucher Senior Medical Fellowship"},{"name":"Mr & Mrs Tam Wing Fan Edmund Renal Research Fund"},{"name":"L & T Charitable Foundation Ltd"}],"content-domain":{"domain":["krcp-ksn.org"],"crossmark-restriction":true},"short-container-title":["Kidney Res Clin Pract"],"published-print":{"date-parts":[[2022,11,30]]},"abstract":"<jats:p>Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition.<\/jats:p>","DOI":"10.23876\/j.krcp.21.285","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T08:04:13Z","timestamp":1658217853000},"page":"682-698","update-policy":"https:\/\/doi.org\/10.23876\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors"],"prefix":"10.23876","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-4090","authenticated-orcid":true,"given":"Anthony T. P.","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6862-1941","authenticated-orcid":true,"given":"Sydney C. W.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"9960","reference":[{"key":"ref1","first-page":"337","volume-title":"An update on the epidemiology of type 2 diabetes: a global perspective","author":"Tinajero","year":"2021"},{"key":"ref2","first-page":"2032","volume-title":"Diabetic kidney disease: challenges, progress, and possibilities","author":"Alicic","year":"2017"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.151"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0234-4"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12073"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0089-4"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(15)00417-9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1096"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-3055"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.120.048740"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1811744"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2024816"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.028268"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy407"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1161\/01.hyp.38.2.155"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/nep.13763"},{"key":"ref18","first-page":"854","volume-title":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0806470"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0802987"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1407963"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2009.02.026"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.18574"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1001286"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-8-201104190-00335"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv272"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.11.003"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa011303"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0801317"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa011161"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1007994"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa643"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000437542.77175.a0"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m116.730564"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-02007-2"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118592"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0172-3"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/1535370219876531"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1159\/000341454"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00128.2020"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.2337\/db17-1212"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-010-2028-x"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2019.10.008"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00394.2015"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3128"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12808"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14175"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14067"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14410"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1159\/000510255"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173721"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1603827"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1616011"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607141"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2108269"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30268-7"},{"key":"ref57","first-page":"131","volume-title":"Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial","author":"Gerstein","year":"2019"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30104-9"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12986"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2020.10.008"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0198-2"},{"key":"ref62","first-page":"2019-vol4","volume-title":"[Antifibrotic renal role of mineralcorticoid receptor antagonists]","author":"Ocello","year":"2019"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpy120"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.117.10360"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-016-0337-0"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190306162658"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1210\/en.2006-0944"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0000000000000091"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2016.11.021"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081"},{"key":"ref71","first-page":"1715","volume-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","author":"Ito","year":"2020"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01963-z"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2025845"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.120.051898"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2021070942"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2110956"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1303154"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1208799"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.114.001624"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2006030208"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2415-y"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2009060593"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2008050482"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.119.12919"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.110.167486"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1161\/hypertensionaha.109.132670"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)61500-2"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2013080830"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010080869"},{"key":"ref90","first-page":"1937","volume-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","author":"Heerspink","year":"2019"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2021040498"}],"container-title":["Kidney Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/krcp-ksn.org\/upload\/pdf\/j-krcp-21-285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/krcp-ksn.org\/journal\/view.php?doi=10.23876\/j.krcp.21.285","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/krcp-ksn.org\/upload\/pdf\/j-krcp-21-285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T01:22:19Z","timestamp":1669771339000},"score":1,"resource":{"primary":{"URL":"http:\/\/krcp-ksn.org\/journal\/view.php?doi=10.23876\/j.krcp.21.285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,30]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"URL":"https:\/\/doi.org\/10.23876\/j.krcp.21.285","relation":{},"ISSN":["2211-9140"],"issn-type":[{"value":"2211-9140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,30]]},"assertion":[{"value":"2021-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-19","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-30","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}